Starting Peptide Therapy: What to Expect at Every Step

From your first consultation to dose titration and follow-up, here is exactly what starting peptide therapy looks like, what labs you need, and how long results take.

What actually happens when you start peptide therapy?

Peptide therapy is a physician-supervised process that moves through four distinct stages: a goal-setting consultation, a targeted lab panel, a personalized protocol matched to your results, and a structured follow-up schedule that adjusts your dose as your body responds. It is not a single injection and a handshake. The whole process is designed to catch problems early and confirm that what you are taking is actually working.

Most programs open with a conversation about what you are trying to address, whether that is body composition, recovery, sleep, or appetite regulation. From there, labs are ordered. Structured, monitored onboarding matters: research on growth hormone secretagogues such as macimorelin shows that even a single week of therapy produces measurable changes in quality-of-life scores and body weight, and longer administration is needed to confirm benefit [1]. Anamorelin, a related oral ghrelin-receptor agonist, demonstrated improvements in lean body mass and appetite in cancer cachexia trials only after consistent daily dosing over multiple weeks [2].

A typical starting sequence looks like this:

• ▶Week 1-2: Consultation, labs ordered, baseline recorded
• ▶Week 2-4: Protocol written, first dose dispensed
• ▶Month 1-3: Dose titration based on labs and reported response
• ▶Month 3+: Quarterly follow-up, labs repeated

Early monitoring is not bureaucratic overhead. Data from appetite-hormone research confirms that the body's hormonal response shifts meaningfully within the first one to twelve weeks of a new agent [3], which is exactly why follow-up is built into the schedule rather than left optional.

The first appointment is where all of this starts, and it is more thorough than most patients expect.

What does the first peptide consultation cover?

The first consultation is a structured clinical intake, not a sales conversation. A physician reviews your goals, your medical history, and any labs you already have, then maps all three against the available protocols before recommending anything.

Goals that drive protocol selection

What you want to accomplish shapes everything downstream. The three most common goal clusters a clinician will ask you to rank are body composition (fat loss, muscle preservation), recovery and sleep quality, and metabolic health. These are not interchangeable. A patient prioritizing visceral fat reduction lands on a different protocol than one focused on post-workout tissue repair. Knowing your priority lets the physician reason from outcome to mechanism, rather than picking a peptide and hoping it fits.

If you are unsure how to frame your goals, reviewing how to read your hormone lab report before your appointment gives you a shared vocabulary for the conversation.

Medical history: red flags and contraindications

The physician will ask about personal or family history of cancer, active autoimmune conditions, uncontrolled diabetes, prior pituitary or thyroid disorders, and any use of growth-hormone-related compounds. These are not formalities. Growth hormone secretagogues, the peptide class that stimulates your body's own growth hormone release, work through a receptor called GHS-R1a. A 2023 pilot trial evaluating macimorelin, a compound in this class, specifically screened participants for cancer history before enrollment because of the theoretical concern that elevated IGF-1 (insulin-like growth factor-1, a downstream signal of growth hormone) could accelerate cell proliferation in susceptible individuals [1].

IGF-1 is the biomarker your physician will watch closely. Think of it as the readout your liver produces when growth hormone is doing its job.

Your age also matters more than most patients realize. The age at which hormone optimization becomes appropriate informs the starting-dose reasoning your physician will walk through with you.

With goals documented and contraindications cleared, the conversation shifts to labs.

Which labs do you need before your first peptide prescription?

You need a baseline lab panel before any peptide protocol starts. There are no exceptions. The panel does two things: it rules out conditions that make certain peptides unsafe, and it gives your clinician the numbers needed to set a starting dose and measure whether the protocol is working.

The baseline lab panel explained

Every patient gets the same core draw before a first prescription:

Why IGF-1 is the key peptide-specific biomarker

IGF-1, or insulin-like growth factor 1, is the messenger that growth hormone sends to your muscles, bones, and organs after it leaves the pituitary gland. Think of growth hormone as the order and IGF-1 as the delivery confirmation. A baseline IGF-1 that is already high tells a clinician to hold or reduce a starting dose; a low reading tells them there is room to move. The pilot trial of macimorelin, a growth hormone secretagogue in the same drug class as many peptides, tracked IGF-1 as the primary efficacy endpoint, which reflects how central this marker is to the entire GH-axis category [1].

Knowing how to read these numbers yourself saves confusion later. The

How is a peptide protocol selected for you specifically?

Your protocol is built from your lab results, your goals, and your health history combined. No two are the same, and that is not marketing language; it reflects the fact that a 45-year-old with low IGF-1 (insulin-like growth factor 1, the hormone that signals tissue repair and body composition) and poor sleep has a different physiological starting point than a 38-year-old managing a soft-tissue injury with normal baseline labs.

Peptide classes and what they target

The table below maps the most commonly prescribed peptides to their primary target, the typical candidate, and how they are delivered.

All injectable peptides require reconstitution from a licensed compounding pharmacy and are administered subcutaneously, meaning a small injection just under the skin, similar to an insulin shot. For a detailed walkthrough of injection technique and site rotation, the TRT injection guide covers the same subcutaneous principles that apply here.

If the distinction between growth hormone peptides matters to you, sermorelin vs tesamorelin lays out the clinical differences in depth. For a focused look at BPC-157's evidence base, BPC-157 peptide therapy is worth reading alongside this.

Why dose titration is built into every protocol

Starting low and adjusting upward is standard practice, not caution for its own sake.

Who is a good candidate, and who should wait?

Most healthy adults with a clear, measurable goal fit the profile: body composition, recovery, metabolic health, or age-related changes in energy and muscle that labs can track. The stronger the baseline data, the cleaner the candidate selection.

A few situations call for a pause before starting:

• ▶Active malignancy. Growth hormone secretagogues stimulate IGF-1, a growth factor your body uses to build tissue. That same signal can be unwanted in an active cancer context, so any history of cancer requires oncology clearance first.
• ▶Autoimmune diabetes (LADA). Latent autoimmune diabetes in adults looks like type 2 diabetes early on but has a different mechanism. A 2026 retrospective study found semaglutide produced meaningful glycemic benefit in LADA patients with preserved beta-cell function, but 12 of 80 patients discontinued treatment, and the effects were substantially weaker in those with poor remaining insulin-producing capacity [5]. GLP-1-class peptides in this population require careful endocrinology oversight.
• ▶Pregnancy or active breastfeeding. Safety data for most peptides in pregnancy is absent. This is a hard stop.
• ▶Uncontrolled thyroid disease. Thyroid status shapes how the body handles both growth hormone and metabolic peptides; normalizing it first makes protocol response far more predictable.

Ideal candidates tend to have stable metabolic health, realistic timelines, and a willingness to track labs. Elevated BMI paired with insulin resistance is actually a strong positive indicator for GLP-1-class protocols, as metabolic dysfunction is exactly what these agents address [6]. Men dealing with the obesity-testosterone feedback loop and those focused on performance without fertility compromise often fit this profile well.

With candidacy established, the follow-up cadence is what keeps the protocol safe and adjustable.

What is the follow-up cadence, and when will you feel results?

Most patients notice the first meaningful changes, better sleep depth and sharper morning energy, within three to six weeks of reaching a stable dose. The mechanisms take time: growth hormone secretagogues work by rebuilding your body's own pulsatile growth hormone release, a rhythm that was blunted gradually and recovers the same way.

The first 90 days: what changes and when

A structured recheck schedule keeps the protocol safe and lets your physician adjust before a small mismatch becomes a persistent problem. A typical cadence looks like this:

IGF-1, short for insulin-like growth factor 1, is the hormone your liver makes in response to growth hormone. Think of it as the downstream messenger that tells your tissues to repair and rebuild. Keeping it within a target range, not too low to be ineffective, not too high to raise safety flags, is the primary lab goal of the six-week recheck.

A six-month review window is consistent with how structured endocrine monitoring is applied in published peptide and GLP-1 research; a 2026 study in The Journal of Clinical Endocrinology and Metabolism tracked patients through six-month intervals to capture meaningful changes in glycemic markers and body composition [5].

What happens if you stop

Benefits are not self-sustaining once you discontinue. A large Swedish registry study published in The Lancet Psychiatry found that protective effects associated with GLP-1 receptor agonists attenuated meaningfully after day 182 post-discontinuation [7], a pattern that likely applies across hormone-axis therapies generally. Your physician will discuss how to taper or transition if circumstances change.

For a parallel look at how timeline expectations apply to testosterone therapy,

What should you bring up with your clinician before you start?

Tell your clinician everything, because gaps in history are the most common reason a protocol gets adjusted after the first month rather than dialed in from day one.

Before your first visit, think through these areas:

• ▶Current medications and supplements. Some compounds affect the same receptors peptides target. Nothing is too minor to mention.
• ▶Fertility goals. Certain protocols can affect reproductive hormones. If family planning is on the table, say so upfront. Your clinician can structure the protocol to protect fertility from the start, a topic covered in depth in the optimizing male performance without compromising fertility guide.
• ▶Comorbidities. Autoimmune conditions, kidney or liver disease, and active cancer diagnoses all shape which options are appropriate and which carry added risk.
• ▶Your primary goal. Recovery, body composition, sleep, energy: each points toward a different agent and different success metrics.
• ▶Patient-reported outcomes you care about. Structured tools that track fatigue, appetite, and quality of life have proved useful in trials of similar agents [2], and your answers help your clinician measure whether the protocol is actually working for you.

Informed consent is not a formality. Read what you sign, ask what each monitoring lab is checking for, and flag any concern before the first dose rather than after.

If you are ready to work through these questions with a physician, a consultation with our clinical team is the practical next step.

MORE FROM THE JOURNAL